Evidence map›Paper›PMID 41060257›Full record

ReviewEmerging microbes & infections2025

Hope and hurdles: unlocking the potential of modified live virus vaccines for African swine fever.

Xinxin Niu, Dongdong Shen, Zhigao Bu, Linda K Dixon, Dongming Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinxin NiuState Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.ORCID 0009-0001-3230-838X
Dongdong ShenState Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.ORCID 0009-0005-6518-7405
Zhigao BuState Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.ORCID 0000-0001-9242-4211
Linda K DixonThe Pirbright Institute, Woking, Surrey, UK.ORCID 0000-0003-3845-3016
Dongming ZhaoState Key Laboratory for Animal Disease Control and Prevention, National African Swine Fever Para-reference Laboratory, National High Containment Facilities for Animal Diseases Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.ORCID 0000-0001-7161-6214

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

African swine fever (ASF), caused by the African swine fever virus (ASFV), poses a serious threat to the global swine industry, causing substantial economic losses and raising significant concerns for food security. The virus' s complex pathogenesis and our limited understanding of its immune evasion mechanisms remain major obstacles to vaccine development. Among current strategies being pursued, modified live virus (MLV) vaccines, despite ongoing safety concerns, have shown the greatest potential to elicit protective immunity. Currently, MLV vaccines are the only ASFV vaccines approved for commercial use. This review summarizes recent advances in ASF MLV research, with a focus on the effects of gene-deleted MLVs on protective efficacy and safety, and provides a comprehensive catalog of all currently identified single-gene and multi-gene targets. Finally, it discusses the key technical, safety, and regulatory challenges that must be addressed to facilitate the development and deployment of ASF MLV vaccines.

Indexed as

African Swine FeverAfrican Swine Fever VirusViral VaccinesAnimalsSwineVaccine DevelopmentVaccines, AttenuatedVaccines, AttenuatedViral VaccinesAfrican swine fever virusgene-deleted targetsmodified live virus vaccinevaccinevaccine candidates

Identifiers

PMID41060257
PMCPMC12551017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.